Histone H3K27Me3 (21-44)-GK-biotin (trifluoroacetate salt)
(Synonyms: ATKAAR-K(Me3)-SAPATGGVKKPHRYRPG-GK(Biotin), H3(21-44)K27me3 Substrate, Histone H3 (21-44) (Lys27me3), Lys(Me3)27-Histone H3 (21-44)-GK(Biotin)) 目录号 : GC43849
A biotinylated peptide fragment of histone H3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Histone H3K27Me3 (21-44)-GK-biotin is a peptide fragment of histone H3 that corresponds to amino acid residues 22-45 of the human histone H3.1 and 3.2 sequences. It is trimethylated at lysine 27 and biotinylated via a C-terminal GK linker. Trimethylation of histone H3 at lysine 27 is associated with gene silencing. It is involved in tumor progression through its regulation by enhancer of zeste homolog 2 (EZH2) and transcriptional repression of tumor suppressor genes. Levels of H3K27Me3 are reduced in 293 T-REx cells containing EEDR236T and SUZ12G610V mutations and in lymphoblastoid cells isolated from patients with Weaver syndrome, a rare overgrowth disorder characterized by EZH2, EED, or SUZ12 mutations, cancer susceptibility, and various distinctive physical features. Histone H3K27Me3 (21-44)-GK-biotin has been used as a substrate for histone lysine demethylases (KDMs) to determine substrate specificity.
| Cas No. | SDF | ||
| 别名 | ATKAAR-K(Me3)-SAPATGGVKKPHRYRPG-GK(Biotin), H3(21-44)K27me3 Substrate, Histone H3 (21-44) (Lys27me3), Lys(Me3)27-Histone H3 (21-44)-GK(Biotin) | ||
| 分子式 | C130H220N44O33S•XCF3COOH | 分子量 | 2959.5 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3379 mL | 1.6895 mL | 3.3789 mL |
| 5 mM | 0.0676 mL | 0.3379 mL | 0.6758 mL |
| 10 mM | 0.0338 mL | 0.1689 mL | 0.3379 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。